MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma by Sadones, J, Michotte, A, Veld, P, Chaskis, C, Sciot, R, Menten, J, Joossens, E.J.R, Strauven, T, D’Hondt, L.A, Sartenaer, D, Califice, S.F.E.H, Bierau, K, Svensson, C, De Grève, J, Neyns, B

Get full text